SciELO - Scientific Electronic Library Online

 
vol.51 número5Social determinants of tuberculosis via a zero-inflated model in small areas of a city in Southeastern BrazilDelayed healthcare and secondary infections following freshwater stingray injuries: risk factors for a poorly understood health issue in the Amazon índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

Compartilhar


Revista da Sociedade Brasileira de Medicina Tropical

versão impressa ISSN 0037-8682versão On-line ISSN 1678-9849

Rev. Soc. Bras. Med. Trop. vol.51 no.5 Uberaba set./out. 2018

http://dx.doi.org/10.1590/0037-8682-0136-2018 

Major Article

Distribution of clinical isolates of Candida spp. and antifungal susceptibility of high biofilm-forming Candida isolates

Gulcan Sahal1 

Isil Seyis Bilkay1 

1Biotechnology Section, Department of Biology, Hacettepe University, Ankara, Turkey.


Abstract

INTRODUCTION:

The increase in the incidence of fungal infections, especially those caused by Candida albicans and other Candida species, necessitates the understanding and treatment of Candida-associated infections. In this study, we aimed to investigate the identification, distribution, and biofilm formation ability of different clinical Candida isolates and evaluate the distribution and antifungal susceptibilities of high biofilm-forming (HBF) Candida isolates.

METHODS:

For identification, carbohydrate fermentation, carbohydrate assimilation, and ChromAgar tests were used. Biofilm formation was assessed using crystal violet binding assay, while the susceptibility to antifungal agents was determined using ATBTM Fungus 3 test kits.

RESULTS:

The majority of Candida species were C. parapsilosis (31.3%; 31/99) and C. tropicalis (30.3%; 30/99). C. tropicalis was found to be the most frequently isolated species among all HBF Candida species. HBF Candida isolates were more frequently isolated from vaginal swab (35.7%; 10/28), tracheal aspirate (17.9%; 5/28), and urine (17.9%; 5/28). The majority of tested isolates were resistant to itraconazole and voriconazole, whereas no isolate was deemed resistant to 5-flucytosine.

CONCLUSIONS:

C. tropicalis displays the highest biofilm formation ability among all the Candida species evaluated, and HBF Candida isolates were more frequently seen in vaginal swab, tracheal aspirate, and urine samples. Our findings revealed that 5-flucytosine is the most efficient antifungal agent against HBF Candida isolates.

Keywords: Antifungal resistance; Biofilm formation; Candida albicans; Non-Candida albicans; Candida Species; 5-Flucytosine

INTRODUCTION

Candida species are natural colonizers of gastrointestinal and urogenital tracts and known to reside as commensals in the oral and conjunctival flora of the healthy human body1. These organisms are known as opportunistic pathogens that may cause various infections ranging from oral candidiasis and esophagitis to hospital-acquired blood stream infections2-4. Although Candida albicans has been reported as the most predominant Candida species that frequently causes invasive fungal infections, a significant increase in non-C. albicans Candida (NCAC) species such as Candida glabrata, Candida krusei, Candida tropicalis, and Candida parapsilosis in human candidiasis has also been indicated over the last decade2,4,5. The increase in the occurrences of all NCAC species as pathogens has led to improvements in diagnostic methods that can sensitively differentiate between NCAC and C. albicans5. On the other hand, the widespread use of a broad range of medical implant devices and an increase in patients that receive immunosuppressive therapy have led to the colonization of different Candida species and various Candida infections2,6. Biofilm formation is one of the most important reasons involved in the transformation of Candida species into important human pathogens6. Biofilm formation is responsible for many problems, as it avoids penetration and diffusion of various antimicrobial agents, causes generation of biofilm cells that have physiological and metabolic alterations, and provides a suitable environment for horizontal gene transfer mechanisms, which play an important role in antimicrobial resistance7,8. As biofilm environments are suitable for the acquisition of new traits via horizontal gene transfer9, investigation of the antifungal resistance of Candida isolates with biofilm formation ability and determination of effective antifungal agents against these isolates are necessary to prevent biofilm-associated Candida infections. In this study, we aimed to identify different clinical Candida isolates, determine their biofilm formation ability, and investigate the susceptibility of high biofilm-forming (HBF) Candida isolates to antifungal agents.

METHODS

Microorganisms

We evaluated 99 clinical Candida isolates that were randomly collected from patients treated at two different hospitals in Ankara, Turkey, between July 2005 and March 2014. Collected isolates were inoculated into the brain heart infusion (BHI) broth (Lab M Ltd, Lancashire, UK) media supplemented with 10% glycerol and stored at -20°C for use in further experiments.

Identification tests

Colony morphologies and microscopic images of collected isolates were examined. By visual inspections, cells and colonies suspected to be Candida were subjected to carbohydrate fermentation, carbohydrate assimilation, and ChromAgar tests.

Carbohydrate fermentation tests

Carbohydrate fermentation tests were performed as per the method described by Bhavan10, with some modifications. Briefly, nutrient broth media supplemented with 1% (v/v) bromothymol blue as a pH indicator and carbohydrates such as glucose, galactose, lactose, maltose, and sucrose were separately prepared. A total of 10μL of each Candida isolate suspended in McFarland 0.5 standard in 5mL of saline buffer was added into 96 wells containing 100μL of different carbohydrate media. The plates were incubated at 37°C for 48h. Fermentation of any carbohydrate was considered as positive upon the change in the color of bromothymol blue to yellow. A total of 99 Candida isolates were identified according to their positive/negative carbohydrate fermentation test results, as presented in Table 1 4,11-15.

TABLE 1: Carbohydrate fermentation and carbohydrate assimilation test results of different Candida species. 

Carbohydrate fermentation Carbohydrate assimilation Candida species
Gl Ga S M L Gl Ga L M X R S
+ +/− + + + + +/− +/− C. albicans
+ + +/- + + + + + +/− C. tropicalis
+ + +/− C. glabrata
+ +/− + + + + + C. parapsilosis
+ + + + + + + +/− + + C. kefyr
+ +/− + +/− C. krusei

Gl: glucose; Ga: galactose: L: lactose; M: maltose; R: raffinose; S: sucrose; X: xylose.

Carbohydrate assimilation tests

Carbohydrate assimilation tests were carried out as per the method described by Marinho et al.4, with some modifications. Briefly, 2% (w/v) carbohydrate solutions of glucose, galactose, lactose, maltose, sucrose, xylose, and raffinose were separately prepared and deposited onto sterile blotting paper discs prepared from eight layers of Whatman No. 1 filter paper. Each Candida isolate suspended in McFarland 0.5 standard in 5mL of saline buffer was inoculated onto 1% yeast nitrogen base (YNB) agar medium (Difco™). The sterile carbohydrate discs were placed onto the agar plates and the plates were incubated at 37°C for 48h. Assimilation of any carbohydrate was considered as positive with a presence of a growth zone around the carbohydrate disc. A total of 99 Candida isolates were identified according to their positive/negative carbohydrate assimilation test results, as presented in Table 1 4,11-15.

Growths on chromagar media

Each Candida isolate was inoculated into CHROMagar™ Candida medium; (CAC, Becton Dickinson, Heidelberg, Germany), which is designed to identify different Candida species based on their colony colors and morphologies. All plates were incubated at 37°C for 48h and visually observed after incubation. A total of 99 Candida isolates were identified according to their colony morphologies on CHROMAgar™ Candida medium. In CHROMAgar™ Candida medium, smooth colonies that appear light to medium green were considered as C. albicans; while dark blue to metallic blue smooth colonies were considered as C. tropicalis. Pink colonies with a whitish rough border were deemed as C. krusei, whereas pink-lavender smooth colonies were considered as C. glabrata. In addition, pink-salmon smooth colonies were deemed as Candida kefyr, while white-pale pink smooth colonies were considered as C. parapsilosis4,11-15.

18S ribosomal RNA gene sequence analysis

Within 99 Candida isolates, Candida isolates that could not be identified by the identification tests used in this study were identified by 18S ribosomal ribonucleic acid (rRNA) gene sequence analysis (RefGen Biotechnology Co. Ltd., Ankara, Turkey).

Biofilm formation on 24-well polystyrene plates

Biofilm formation abilities of 99 different Candida isolates were determined by crystal violet binding assay described by O’Toole16, with some modifications. Briefly, single yeast colonies were picked-up from BHI agar plate and inoculated into 10-mL BHI broth medium and incubated at 37°C overnight. The overnight culture was 1:100 diluted into fresh BHI medium and the wells of a polystyrene plate were filled with 1mL of the diluted inoculum. The plates were incubated for 48h at 37°C. After incubation, the medium was gently removed and the wells were gently washed with sterile distilled water. After allowing wells to dry, each well was stained with 1% (w/v) crystal violet (Merck)/sterile distilled water for 45 min at 25°C. Excess of crystal violet was removed by sterile distilled water and the bound crystal violet in each well was solubilized by adding 1mL of ethanol (96.6%) solution. Solubilized crystal violet from each well was read by a spectrophotometer (Shimadzu UV - 1700, Kyoto, Japan) at 560nm wavelength. According to biofilm formations, Candida isolates were classified into four categories as follows:

  • 0 ≤ OD < 0.4: non biofilm former (NBF)

  • 0.4 ≤ OD < 0.8: low biofilm former (LBF)

  • 0.8 ≤ OD < 1.2: intermediate biofilm former (IBF)

  • OD ≥ 1.2: high biofilm former (HBF)

  • The experiment was performed in triplicates.

Antifungal susceptibility tests

Antifungal susceptibilities of HBF Candida isolates [optical density (OD) ≥ 1.60] were determined by ATBTM Fungus 3 test kits (BioMérieux®, France). Antifungal susceptibilities of 25 HBF Candida isolates against 5-flucytosine, fluconazole, itraconazole, and voriconazole were evaluated. Briefly, all isolates were inoculated onto sabouraud dextrose agar (SDA) and incubated at 37°C for 48h. After incubation, each Candida isolate was suspended in saline solution, and yeast cells corresponding to a 2.0 McFarland standard were added into ATB F2 medium (yeast nitrogen base 6.7g; glucose 6.5g; asparagine 1.5g; disodium phosphate 2.5g; trisodium citrate 2.5g; potassium nitrate 5.5g; demineralized water 1,000mL; pH: 6.5-6.8). ATB F2 media with different Candida isolates were transferred into antifungal test strips and all the test strips were incubated at 37°C for 48h. After incubation, minimum inhibitory concentrations (MICs) of antifungal agents were visually determined and all the isolates were classified as resistant (R), intermediate (I), or sensitive (S) according to the MIC standards constituted by the Clinical and Laboratory Standards Institute (CLSI) (M27-A3, 2008)17. Breakpoints (mg/L) for Candida spp. were as follows:

Statistical analysis

Chi-square analysis was applied to estimate differences between the effects of four different antifungal agents. Bonferroni post-hoc test was used to evaluate antifungal susceptibility and agents with more/less significant effects were estimated. The significance level was set at 5% and the difference between the effects of each antifungal agent was considered as significant when p-value < 0.05. Statistical analysis was performed using Statistical Package for Social Sciences (SPSS) 20.0 Software (IBM Corp, New York, USA).

RESULTS

According to all phenotypic identification tests, six different Candida species, namely, C. kefyr (n = 1), C. glabrata (n = 8), C. albicans (n = 13), C. krusei (n = 15), C. tropicalis (n = 30), and C. parapsilosis (n = 31) were identified in this study. One of the Candida isolates could not be clearly identified by phenotypical methods and was thought to be C. tropicalis or C. krusei. The results of 18S ribosomal RNA gene sequence analysis identified this strain as Candida orthopsilosis.

The frequencies of different Candida species isolated in this study show that most of the Candida species were C. parapsilosis (31.3%; n = 31) and C. tropicalis (30.3%; n = 30), followed by C. krusei (15.2%; n = 15), C. albicans (13.1%; n = 13), C. glabrata (8.1%; n = 8), C. kefyr (1%; n = 1), and C. orthopsilosis (1%; n = 1). Furthermore, the majority of Candida isolates were observed to be isolated from vaginal swab (49.5%; n = 49), followed by specimens of tracheal aspirate (10.1%; n = 10), blood (9.1%; n = 9), sputum (9.1%; n = 9), urine (8.1%; n = 8), bronchoscopic culture (5.1%; n = 5), wound (3%; n = 3), bronchial lavage (1%; n = 1), thoracentesis (1%; n = 1), eye (1%; n = 1), synovial fluid (1%; n = 1), and catheter (1%; n = 1). The examination of the distribution of different Candida species in different clinical specimens revealed C. tropicalis as the most frequent Candida species isolated from tracheal aspirate and urine specimens, while most of Candida isolates obtained from blood specimen were identified as C. albicans (Figure 1). C. glabrata was the only Candida species isolated from synovial fluid and thoracentesis specimens (Figure 1). However, all isolates obtained from catheter and bronchial lavage were C. tropicalis and all isolates isolated from wound and eye specimens were C. parapsilosis (Figure 1). Among all HBF Candida species such as C. tropicalis, C. parapsilosis, C. glabrata, and C. orthopsilosis, C. tropicalis was found to be the most frequent species (23.2%; n = 23) (Table 2). However, all C. krusei isolates were found as NBF (Table 2). HBF Candida isolates were obtained from clinical samples such as vaginal swab, tracheal aspirate, urine, catheter, sputum, bronchial lavage, bronchoscopic culture, and eye specimens (Figure 2). We evaluated the distribution of all HBF Candida isolates (n = 28) in different clinical materials and found vaginal swab as the most frequent clinical material for HBF Candida isolate isolation (35.7%; n = 10) (Figure 2). Furthermore, frequencies of HBF Candida isolates obtained from tracheal aspirate (17.9%; n = 5), urine (17.9%; n = 5), and sputum (14.3% n = 4) were higher than those of HBF Candida isolates from catheter (3.6%; n = 1), bronchial lavage (3.6%; n = 1), bronchoscopic culture (3.6%; n = 1), and eye (3.6%; n = 1) specimens (Figure 2). The susceptibilities of 25 HBF Candida isolates to 5-flucytosine, fluconazole, itraconazole, and voriconazole were evaluated and all the agents were found to exhibit different effects (Chi-square test, p-value < 0.05). Most isolates were resistant to itraconazole and voriconazole, while all were deemed sensitive to the effect of 5-flucytosine (Figure 3). Among all the antifungal agents used in this study, 5-flucytosine was efficient against HBF Candida isolates (Bonferroni post-hoc test, p-value < 0.00) (Figure 3). Therefore, 5-flucytosine showed higher in vitro activity against all HBF Candida isolates (n = 25) tested (Bonferroni post-hoc test, p-value < 0.00).

FIGURE 1: Distribution of different Candida species in various clinical materials (n = 99 isolates). 

TABLE 2: Frequencies of non-biofilm-forming, low biofilm-forming, intermediate biofilm-forming, and high-biofilm forming Candida species (n = 99 isolates)*. 

NBF (%) LBF (%) IBF (%) HBF (%)
C. albicans 13.1 0.0 0.0 0.0
C. glabrata 5.1 0.0 2.0 1.0
C. kefyr 0.0 1.0 0.0 0.0
C. krusei 15.2 0.0 0.0 0.0
C. orthopsilosis 0.0 0.0 0.0 1.0
C. parapsilosis 25.3 3.0 0.0 3.0
C. tropicalis 6.1 0.0 1.0 23.2

NBF: non-biofilm-forming; LBF: low biofilm-forming; IBF: intermediate biofilm-forming; HBF: high biofilm-forming; OD: optical density. *Biofilm groups have been generated according to biofilm formation OD of tested Candida isolates given as follows: NBF: 0 ≤ OD < 0.4; LBF: 0.4 ≤ OD < 0.8; IBF: 0.8 ≤ OD < 1.2; HBF: OD ≥ 1.2.

FIGURE 2: Distribution of HBF Candida isolates in different clinical materials (n = 28 isolates). HBF: high biofilm-forming. 

FIGURE 3: Antifungal susceptibilities of HBF Candida isolates (biofilm formation OD ≥ 1.60) (n = 25 isolates.). All antifungal agents had significantly different effects (Chi-square test, p-value < 0.05). HBF: high biofilm-forming; OD: optical density. *Indicates that the tested HBF Candida isolates were significantly more sensitive to 5-flucytosine than to other antifungal agents used in this study (Bonferroni post-hoc test, p-value < 0.00). **Indicates that the tested HBF Candida isolates were significantly less sensitive to voriconazole than to other antifungal agents used in this study (Bonferroni post-hoc test, p-value < 0.00). 

DISCUSSION

In many studies, C. albicans has been regarded as the most prevalent Candida species18,19. However, the results of the present study show that C. parapsilosis and C. tropicalis were observed in high frequencies. In addition, the frequency of C. krusei was higher than that of C. albicans, confirming that the occurrence of NCAC species such as C. tropicalis, C. parapsilosis, and C. krusei is increasing11,18,20 as observed in a recent study. C. tropicalis was indicated as the most prevalent Candida species among all Candida species isolated and is regarded as an important emerging fungal pathogen associated with high mortality rate11. In line with the results of the present study, NCAC species are shown to be more prevalent than C. albicans in pediatric (< 3 year) and older (> 60 year) patients than in patients from other age groups (4-18, 19-60 years) and intensive care unit (ICU) patients21. According to other studies carried out with neonates, the prevalence of C. parapsilosis was higher than that of C. albicans, and C. parapsilosis has been indicated as a predominant pathogen of invasive candidiasis in neonates22,23.

Urine, vaginal swab, blood, indwelling biomaterial, and respiratory tract samples are found to be the most prevalent specimens for Candida isolation11,21,24. In parallel with these findings, the majority of Candida isolates were isolated from vaginal swab specimen, followed by specimens of tracheal aspirate, blood, sputum, and urine. However, C. tropicalis was found as the most frequent Candida species in tracheal aspirate and sputum specimens (Figure 1), contradicting the results of previous studies on the predominance of C. albicans in lower respiratory tract specimens12,25. The most prevalent Candida species isolated from blood was C. albicans, confirming that C. albicans remains the most frequent fungal species in blood specimen18.

The investigation of the distribution of Candida species in different biofilm groups showed that C. tropicalis, which was more frequently isolated in this study, was also found as the most prevalent HBF Candida species, whereas all other C. albicans isolates were NBFs (Table 2). Therefore, the predominance of C. tropicalis instead of C. albicans was thought to be related to its enhanced biofilm formation ability24.

Applications of temporary or permanent biomaterials and medical devices in medicine have particularly led to an increase in the incidence of biofilm-associated infections26,27. One of the clinical specimens positive for HBF Candida isolates was catheter (Figure 2). Furthermore, HBF Candida isolates were more frequently isolated from the clinical specimens (vaginal swab, tracheal aspirate, and urine) that were related to the body parts that may be exposed to biomaterials such as intrauterine devices, endotracheal tubes, and urinary catheters.

The treatment of invasive fungal infections is usually carried out with five major groups of antifungal agents, including azoles, polyenes, allylamines, echinocandins, and pyrimidine analogues28. Fluconazole, voriconazole, and itraconazole belong to azole class, while 5-flucytosine is a pyrimidine analogue (Figure 3). Of these, azoles that target ergosterol biosynthesis via blockage of the enzyme lanosterol 14a-demethylase28 are the most widely used group of antifungal agents29. A recent study evaluating the susceptibilities of different Candida species to fluconazole, voriconazole, itraconazole, ketoconazole, and 5-flucytosine showed that the majority of Candida isolates were sensitive to fluconazole and 5-flucytosine30. However, 5-flucytosine known to inhibit both ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) synthesis after being converted to 5-fluorouracil31 was the most effective antifungal agent against all HBF Candida species tested in the present study (Figure 3).

The high resistance to fluconazole may be mainly related to the high biofilm formation ability of the tested Candida isolates. Biofilms are known as suitable environments for horizontal gene transfer mechanisms32. Therefore, high biofilm formation ability may play an important role in the acquisition of new antifungal resistance traits in various Candida species.

Candida tropicalis isolates that demonstrated high biofilm formation capacity were shown to display higher rate of resistance to fluconazole in one of the recent studies33.

In conclusion, the present study shows that C. tropicalis displays the highest biofilm formation ability among the Candida species evaluated. Our findings indicate high frequency of HBF Candida isolation from clinical samples of vaginal swab, tracheal aspirate, and urine. We also found that 5-flucytosine is the most efficient antifungal agent against HBF Candida isolates.

Acknowledgements

The authors are grateful to Abbas Yousefi Rad for the collection of clinical specimens.

REFERENCES

1. Spampinato C, Leonardi D. Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. Biomed Res Int. 2013;2013:1-13: 204237. [ Links ]

2. Sanguinetti M, Posteraro B, Lass-Flörl C. Antifungal drug resistance among Candida species: mechanisms and clinical impact. Mycoses. 2015;58(S2):2-13. [ Links ]

3. Hernandez S, Lo´pez-Ribot JL, Najvar LK, McCarthy DI, Bocanegra R, Graybill JR. Caspofungin resistance in candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother. 2004;48(4):1382-83. [ Links ]

4. Marinho SA, Teixeira AB, Santos OS, Cazanova RF, Ferreira CAS, Cherubini K, et al. Identification of Candida spp. by phenotypic tests and PCR. Braz J Microbiol. 2010;41:286-94. [ Links ]

5. Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J. Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev. 2012;36(2):288-305. [ Links ]

6. Ramage G, Martínez JP, López-Ribot JL. Candida Biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res. 2006;6(7):979-86. [ Links ]

7. Carneiro VA, dos Santos HS, Arruda FVS, Bandeira PN, Albuquerque MRJR, Pereira MO, et al. Casbane diterpene as a promising natural antimicrobial agent against biofilm-associated infections. Molecules. 2011;16(1):190-201. [ Links ]

8. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15(2):167-93. [ Links ]

9. Silva S, Rodrigues CF, Ara D, Rodrigues ME, Henriques M. Candida species biofilms’ antifungal resistance. J Fungi (Basel). 2017;3(1). pii: E8. doi: 10.3390/jof3010008. [ Links ]

10. Bhavan PS, Rajkumar R, Radhakrishnan S, Seenivasan C, Kannan S. Culture and identification of Candida albicans from Vaginal ulcer and separation of enolase on SDS-PAGE. Int J Biol. 2010;2(1):84-93. [ Links ]

11. Yesudhason BL, Mohanram K. Candida tropicalis as a predominant isolate from clinical specimens and its antifungal susceptibility pattern in a Tertiary Care Hospital in Southern India. J Clin Diagn Res. 2015;9(7):DC14-6. [ Links ]

12. Ogba OM, Abia-Bassey LN, Epoke J, Mandor BI, Iwatt GD. Characterization of Candida species isolated from cases of lower respiratory tract infection. World J AIDS 2013;3:201-6. [ Links ]

13. Lachance MA, Boekhout T, Scorzetti G, Fell JW, Kurtzman CP. Candida Berkhout. In: Kurtzman CP, Fell JW, Boekhout T, editors. The yeasts, a taxonomic study. Amsterdam: Elsevier; 2011. p. 987-1278. [ Links ]

14. Manjunath V, Vidya GS, Sharma A, Prakash MR, Murugesh. Speciation of Candida by Hicrome agar and Sugar assimilation test in both HIV infected and non-infected patients. Int J Biol Med Res. 2012;3(2):1778-82. [ Links ]

15. Jose NV, Mudhigeti N, Asir J, Chandrakesan SD. Detection of virulence factors and phenotypic characterization of Candida isolates from clinical specimens. J Curr Res Sci Med. 2015;1:27-31. [ Links ]

16. O’Toole GA. Microtiter dish biofilm formation assay. J Vis Exp 2011; (47):e2437. [ Links ]

17. Clinical and Laboratory Standards Institute (CLSI). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard-Third Edition. Document M27-A3. Wayne, PA: CLSI; 2008. 13p. [ Links ]

18. Wisplinghoff H, Ebbers J, Geurtz L, Stefanik D, Major Y, Edmond MB, et al. Nosocomial bloodstream infections due to Candida Spp. in the USA: species distribution, clinical features and antifungal susceptibilities. Int J Antimicrob Agents. 2014;43(1):78-81. [ Links ]

19. Liu XP, Fan SR, Peng YT, Zhang HP. Species distribution and susceptibility of Candida isolates from patient with vulvovaginal candidiasis in Southern China from 2003 to 2012. J Mycol Med. 2014;24(2):106-11. [ Links ]

20. Almeida AA, Mesquita CS, Svidzinski TI, Oliveira KM. Antifungal susceptibility and distribution of Candida spp. isolates from the University Hospital in the municipality of Dourados, State of Mato Grosso do Sul, Brazil. Rev Soc Bras Med Trop. 2013;46(3):335-9. [ Links ]

21. Pahwa N, Kumar R, Nirkhiwale S, Bandi A. Species distribution and drug susceptibility of candida in clinical isolates from a Tertiary Care Centre at Indore. Indian J Med Microbiol. 2014;32(1):44-8. [ Links ]

22. Garzillo C, Bagattini M, Bogdanović L, Di Popolo A, Iula VD, Catania MR, et al. Risk factors for Candida parapsilosis bloodstream infection in a neonatal intensive care unit: a case-control study. Ital J Pediatr. 2017;43(1):10. [ Links ]

23. Chow BDW, Linden JR, Bliss JM. Candida parapsilosis and the Neonate: Epidemiology, Virulence and Host Defense in a Unique Patient Setting. Expert Rev Anti Infect Ther. 2012;10(8):935-46. [ Links ]

24. Silva AP, Miranda IM, Lisboa C, Pina-Vaz C, Rodrigues AG. Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a Tertiary Care Hospital. J Clin Microbiol. 2009;47(8):2392-97. [ Links ]

25. Bailly S, Maubon D, Fournier P, Pelloux H, Schwebel C, Chapuis C, et al. Impact of antifungal prescription on relative distribution and susceptibility of Candida spp. - Trends over 10 years. J Infect. 2016;72(1):103-11. [ Links ]

26. Junter GA, Thébault P, Lebrun L. Polysaccharide-based antibiofilm surfaces. Acta Biomater. 2016;30:13-25. [ Links ]

27. Dutta Sinha S, Chatterjee S, Maiti PK, Tarafdar S, Moulik SP. Evaluation of the role of substrate and albumin on Pseudomonas aeruginosa biofilm morphology through FESEM and FTIR studies on polymeric biomaterials. Prog Biomater. 2017;6(1-2):27-38. [ Links ]

28. Mathé L, Van Dijck P. Recent Insights into Candida albicans biofilm resistance mechanisms. Curr Genet. 2013;59(4):251-64. [ Links ]

29. Roemer T, Krysan DJ. Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb Perspect Med. 2014;4(5):pii: a019703. doi: 10.1101/cshperspect.a019703. [ Links ]

30. Razzaghi-Abyaneh M, Sadeghi G, Zeinali E, Alirezaee M, Shams-Ghahfarokhi M, Amani A, et al. Species distribution and antifungal susceptibility of Candida spp. isolated from superficial candidiasis in outpatients in Iran. J Mycol Med . 2014;24(2):e43-50. [ Links ]

31. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000;46(2):171-9. [ Links ]

32. Hall-Stoodley L, Stoodley P. Biofilm formation and dispersal and the transmission of human pathogens. Trends Microbiol. 2005;13(1):7-10. [ Links ]

33. Deorukhkar SC, Saini S, Mathew S. Virulence factors contributing to pathogenicity of Candida tropicalis and Its antifungal susceptibility profile. Int J Microbiol. 2014;2014(1):1-6. ID 456878. [ Links ]

Financial support: This study was part of a PhD and was supported by the funding received from Scientific Research Projects Coordination Unit (grant number: FDK-2016-10821) of Hacettepe University.

Received: April 22, 2018; Accepted: August 07, 2018

Corresponding author: Dr. Gulcan Sahal. e-mail:gulcanozbakir@gmail.com

Conflict of interest: The authors declare that there is no conflict of interest.

Creative Commons License This is an open-access article distributed under the terms of the Creative Commons Attribution License